Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Sidse Vang Braa Andersen; Lisbeth Sams⊘ Schmidt; Ulla Birgitte Hartling; Anne Cathrine Viuff; Mette Holm; Lone Graff Stensballe; Marie Louise von Linstow

doi:10.61409/V11250898

Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Translated title of the contribution: Prevention of respiratory syncytial virus in children

Sidse Vang Braa Andersen
, Lisbeth Sams⊘ Schmidt
, Ulla Birgitte Hartling
, Anne Cathrine Viuff
, Mette Holm
, Lone Graff Stensballe
, Marie Louise von Linstow^*

^*Corresponding author for this work

Abstract

Prevention of respiratory syncytial virus in children Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injeetions. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From Oetober 2025, Denmark introduced a seasonal maternal vaccination, expeeted to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

Translated title of the contribution	Prevention of respiratory syncytial virus in children
Original language	Danish
Article number	V11250898
Journal	Ugeskrift for Laeger
Volume	188
Number of pages	9
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V11250898
Publication status	Published - 16 Feb 2026

Access to Document

10.61409/V11250898Licence: CC BY-NC-ND

Cite this

@article{001fdde95f7b45698901ab32bd47c2ef,

title = "Forebyggelse af respiratorisk syncytialvirus-infektion hos sp{\ae}db{\o}rn",

abstract = "Prevention of respiratory syncytial virus in children Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injeetions. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From Oetober 2025, Denmark introduced a seasonal maternal vaccination, expeeted to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.",

author = "Andersen, \{Sidse Vang Braa\} and Schmidt, \{Lisbeth Sams⊘\} and Hartling, \{Ulla Birgitte\} and Viuff, \{Anne Cathrine\} and Mette Holm and Stensballe, \{Lone Graff\} and \{von Linstow\}, \{Marie Louise\}",

year = "2026",

month = feb,

day = "16",

doi = "10.61409/V11250898",

language = "Dansk",

volume = "188",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske L{\ae}geforening",

}

TY - JOUR

T1 - Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

AU - Andersen, Sidse Vang Braa

AU - Schmidt, Lisbeth Sams⊘

AU - Hartling, Ulla Birgitte

AU - Viuff, Anne Cathrine

AU - Holm, Mette

AU - Stensballe, Lone Graff

AU - von Linstow, Marie Louise

PY - 2026/2/16

Y1 - 2026/2/16

N2 - Prevention of respiratory syncytial virus in children Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injeetions. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From Oetober 2025, Denmark introduced a seasonal maternal vaccination, expeeted to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

AB - Prevention of respiratory syncytial virus in children Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injeetions. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From Oetober 2025, Denmark introduced a seasonal maternal vaccination, expeeted to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

UR - https://www.scopus.com/pages/publications/105031191003

U2 - 10.61409/V11250898

DO - 10.61409/V11250898

M3 - Tidsskriftartikel

C2 - 41738099

AN - SCOPUS:105031191003

SN - 0041-5782

VL - 188

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

M1 - V11250898

ER -

Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Abstract

Access to Document

Other files and links

Fingerprint

Cite this